PUBLICATIONS

Zeitlinger M, Bauer M, Reindl-Schwaighofer R, Stoekenbroek RM, Lambert G, Beger-Sieczkowski E, Lagler H, Oesterreicher Z, Wulkersdorfer B, Lührs P, Galabova G, Schwenke C, Mader RM, Medori R, Landlinger C, Kutzelnigg A, Staffler G. A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9. Eur J Clin Pharmacol 77, 1473–1484 (2021).
Bartl S, Oueslati A, Southwell AL, Siddu A, Parth M, David LS, Maxan A, Salhat N, Burkert M, Mairhofer A, Friedrich T, Pankevych H, Balazs K, Staffler G, Hayden MR, Cicchetti F, Smrzka OW. | Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: Implications for the treatment of Huntington's disease | Neurobiol Dis. 2020 Jul;141:104943.
Volc D, Poewe W, Kutzelnigg A, Lührs P, Thun-Hohenstein C, Schneeberger A, Galabova G, Majbour N, Vaikath N, El-Agnaf O, Winter D, Mihailovska E, Mairhofer A, Schwenke C, Staffler G, Medori R. | Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. | Lancet Neurol. 2020 Jul;19(7):591-600.
Mateos B, Sealey-Cardona M, Balazs K, Konrat J, Staffler G, Konrat R. | NMR Characterization of Surface Receptor Protein Interactions in Live Cells Using Methylcellulose Hydrogels | Angew Chem Int Ed Engl. 2020 Mar 2;59(10):3886-3890.
Mandler M, Rockenstein E, Overk C, Mante M, Florio J, Adame A, Kim C, Santic R, Schneeberger A, Mattner F, Schmidhuber S, Galabova G, Spencer B, Masliah E, Rissman RA. | Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies-like model | Alzheimers Dement. 2019 Sep;15(9):1133-1148
Wanko B, Tardelli M, Jürets A, Neuhofer A, Prager G, Morser J, Leung LL, Staffler G, Zeyda M, Stulnig TM. | Antibody-mediated targeting of cleavage-specific OPN-T cell interactions | PLoS One. 2019 Apr 5;14(4):e0214938
Vigl B, Salhat N, Parth M, Pankevych H, Mairhofer A, Bartl S, Smrzka OW. | Quantitative in vitro and in vivo models to assess human IgE B cell receptor crosslinking by IgE and EMPD IgE targeting antibodies | J Immunol Methods. 2017 Oct;449:28-36.
Landlinger C, Pouwer MG, Juno C, van der Hoorn JWA, Pieterman EJ, Jukema JW, Staffler G, Princen HMG, Galabova G | The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice | Eur Heart J 2017;38(32):2499–2507
Grün NG, Zeyda K, Moreno-Viedma V, Strohmeier K, Staffler G, Zeyda M, Stulnig TM | A humanized osteopontin mouse model and its application in immunometabolic obesity studies. | Transl Res 2016;178:63–73.e2
Grün NG, Strohmeier K, Moreno-Viedma V, Le Bras M, Landlinger C, Zeyda K, Wanko B, Leitner L, Staffler G, Zeyda M, Stulnig TM. | Peptide-based vaccination against OPN integrin binding sites does not improve cardio-metabolic disease in mice | Immunol Lett. 2016 Nov;179:85-94.
Amor M, Moreno-Viedma V, Sarabi A, Grün NG, Itariu B, Leitner L, Steiner I, Bilban M, Kodama K, Butte AJ, Staffler G, Zeyda M, Stulnig TM. | Identification of matrix metalloproteinase-12 as a candidate molecule for prevention and treatment of cardiometabolic disease. | Mol Med 2016;22:487–496
Tardelli M, Zeyda K, Moreno-Viedma V, Wanko B, Grün NG, Staffler G, Zeyda M, Stulnig TM. | Osteopontin is a key player for local adipose tissue macrophage proliferation in obesity | Mol Metab. 2016 Sep 13;5(11):1131-1137
Moreno-Viedma V, Amor M, Sarabi A, Bilban M, Staffler G, Zeyda M, Stulnig TM | Common dysregulated pathways in obese adipose tissue and atherosclerosis | Cardiovasc Diabetol 2016;15(1):120
Schneeberger A, Tierney L, Mandler M | Active immunization therapies for Parkinson’s disease and multiple system atrophy | Mov Disord 2016;31(2):214–224
Schuch K, Wanko B, Ambroz K, Castelo-Rosa A, Moreno-Viedma V, Grün NG, Leitner L, Staffler G, Zeyda M, Stulnig TM | Osteopontin affects macrophage polarization promoting endocytic but not inflammatory properties | Obesity (Silver Spring) 2016;24(7):1489–1498
Jürets A, Le Bras M, Staffler G, Stein G, Leitner L, Neuhofer A, Tardelli M, Turkof E, Zeyda M, Stulnig TM | Inhibition of cellular adhesion by immunological targeting of osteopontin neoepitopes generated through matrix metalloproteinase and thrombin cleavage. | PLoS One 2016;11(2):e0148333
Landlinger C, Oberleitner L, Gruber P, Noiges B, Yatsyk K, Santic R, Mandler M, Staffler G | Active immunization against complement factor C5a: a new therapeutic approach for Alzheimer’s disease | J Neuroinflammation 2015;12:150
Mandler M, Valera E, Rockenstein E, Mante M, Weninger H, Patrick C, Adame A, Schmidhuber S, Santic R, Schneeberger A, Schmidt W, Mattner F, Masliah E. | Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy | Mol Neurodegener 2015;10:10
Hendrix S, Ellison N, Stanworth S, Tierney L, Mattner F, Schmidt W, Dubois B, Schneeberger A. | Methodological Aspects of the Phase II Study AFF006 Evaluating Amyloid-beta -Targeting Vaccine AFFITOPE® AD02 in Early Alzheimer's Disease - Prospective Use of Novel Composite Scales | J Prev Alzheimers Dis. 2015 Jun;2(2):91-102
Leitner L, Schuch K, Jürets A, Itariu BK, Keck M, Grablowitz V, Aszmann OC, Prager G, Staffler G, Zeyda M, Stulnig TM | Immunological blockade of adipocyte inflammation caused by increased matrix metalloproteinase-cleaved osteopontin in obesity | Obesity (Silver Spring) 2015;23(4):779–785
Schneeberger A, Hendrix S, Mandler M, Ellison N, Bürger V, Brunner M, Frölich L, Mimica N, Hort J, Rainer M, Imarhiagbe D, Kurz A, Peters O, Gertz HJ, Tierney L, Mattner F, Schmidt W, Dubois B. | Results from a Phase II Study to Assess the Clinical and Immunological Activity of AFFITOPE® AD02 in Patients with Early Alzheimer's Disease | J Prev Alzheimers Dis. 2015;2(2):103-114
Mandler M, Santic R, Gruber P, Cinar Y, Pichler D, Funke SA, Willbold D, Schneeberger A, Schmidt W, Mattner F | Tailoring the antibody response to aggregated Aß using novel Alzheimer-vaccines. | PLoS One 2015;10(1):e0115237
Galabova G, Brunner S, Winsauer G, Juno C, Wanko B, Mairhofer A, Lührs P, Schneeberger A, von Bonin A, Mattner F, Schmidt W, Staffler G. | Peptide-based anti-PCSK9 vaccines – an approach for long-term LDLc management | PLoS One 2014;9(12):e114469
Mandler M, Walker L, Santic R, Hanson P, Upadhaya AR, Colloby SJ, Morris CM, Thal DR, Thomas AJ, Schneeberger A, Attems J | Pyroglutamylated amyloid-β is associated with hyperphosphorylated tau and severity of Alzheimer’s disease | Acta Neuropathol 2014;128(1):67–79
Mandler M, Valera E, Rockenstein E, Weninger H, Patrick C, Adame A, Santic R, Meindl S, Vigl B, Smrzka O, Schneeberger A, Mattner F, Masliah E. | Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials | Acta Neuropathol 2014;127(6):861–879
Neuhofer A, Wernly B, Leitner L, Sarabi A, Sommer NG, Staffler G, Zeyda M, Stulnig TM. | An accelerated mouse model for atherosclerosis and adipose tissue inflammation. | Cardiovasc Diabetol 2014;13:23
Schneeberger A, Mandler M, Mattner F, Schmidt W | Vaccination for Parkinson’s disease | Parkinsonism Relat Disord 2012;18(Suppl 1):S11–S13
Schneeberger A, Mandler M, Mattner F, Schmidt W | AFFITOME® technology in neurodegenerative diseases: the doubling advantage | Hum Vaccin 2010;6(11):948–952
Mandler M, Rockenstein E, Ubhi K, Hansen L, Adame A, Michael S, Galasko D, Santic R, Mattner F, Masliah E. | Detection of peri-synaptic amyloid-β pyroglutamate aggregates in early stages of Alzheimer’s disease and in AβPP transgenic mice using a novel monoclonal antibody. | J Alzheimers Dis. 2012;28(4):783-94.
Schneeberger A, Mandler M, Otawa O, Zauner W, Mattner F, Schmidt W. | Development of AFFITOPE vaccines for Alzheimer’s disease (AD)–from concept to clinical testing. | J Nutr Health Aging 2009;13(3):264–267